Skip to main content

BHR-100 FDA Approval Status

FDA Approved: No
Brand name: BHR-100
Generic name: progesterone
Dosage form: Intravenous Infusion
Company: BHR Pharma, LLC
Treatment for: Head Injury

BHR-100 is a proprietary intravenous progesterone infusion product in development as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients.

Development timeline for BHR-100

Sep  3, 2013BHR Pharma Announces SyNAPSe® Trial Completes Patient Enrollment
Dec  8, 2009BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.